BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celleration, Inc. Closing in on $7 Million Round of Funding


1/15/2013 8:09:36 AM

Wound-healing med-tech firm Celleration Inc. is close to wrapping up a $7 million round of financing as it expands product sales into the U.K. The Eden Prairie-based company makes a device called Mist Therapy, which uses ultrasonic waves to treat stubborn-to-heal wounds such as diabetic foot ulcers. Celleration’s technology emits ultrasonic vibrations and delivers a mist to injured tissue. The mist removes bacteria and stimulates cells, helping wounds heal. The treatment is painless, and it targets wounds in the lower extremities. Celleration raised its recent round of financing from previous investors and high net-worth individuals, said Celleration CEO Mark Wagner. The company’s past investors include Minneapolis-based venture-capital firm SightLine Partners, Cedar Rapids, Iowa-based Aavin Equity Advisors, Minneapolis-based Affinity Capital Management, and Chicago-based Baird Venture Partners. The fund-raising environment for med-tech firms is challenging, partly due to a new excise tax on medical devices that went into effect this year, Wagner said. The company succeeded partly due to its device’s long track record, as Mist has now been used to treated one million patients, he said.

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES